<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03445793</url>
  </required_header>
  <id_info>
    <org_study_id>HS-3145</org_study_id>
    <nct_id>NCT03445793</nct_id>
  </id_info>
  <brief_title>: TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)</brief_title>
  <official_title>: TRANSITION: An Observational Study of the Effects on Sweat Chloride and Clinical Outcomes of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single center study of clinical and laboratory outcomes in patients â‰¥ 12 who
      transition from use of Orkambi to tez/iva. Clinical and laboratory measurements will be
      measured at baseline, 1 month, 3 months, and 6 months after initiation of tez/iva. The length
      of study participation will be approximately 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in sweat chloride concentration in millimoles/liter</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rationale for transition per physician questionnaire</measure>
    <time_frame>1 day (the questionnaire is done once at visit 1)</time_frame>
    <description>Questionnaire to determine the treating physician's reason for transition to tezacaftor/ivacaftor from lumacaftor/ivacaftor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rationale for transition per subject questionnaire</measure>
    <time_frame>1 day (the questionnaire is done once at visit 1)</time_frame>
    <description>Questionnaire to determine the subject's reason for transition to tezacaftor/ivacaftor from lumacaftor/ivacaftor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of pulmonary exacerbations</measure>
    <time_frame>6 months</time_frame>
    <description>Determination of the occurrence of the number of pulmonary exacerbations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>spirometry measurements in liters</measure>
    <time_frame>6 months</time_frame>
    <description>Measure of lung function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score in whole numbers</measure>
    <time_frame>6 months</time_frame>
    <description>CF-related quality of life measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CFQ-R Gastro-Intestinal score in whole numbers</measure>
    <time_frame>6 months</time_frame>
    <description>CF-related quality of life measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight in kilograms</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI in kilograms/meter squared</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fecal elastase in micrograms/gram</measure>
    <time_frame>6 months</time_frame>
    <description>Measure of pancreatic function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transaminase measurements in Units/Liter</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchodilator requirements in doses/day</measure>
    <time_frame>6 months</time_frame>
    <description>Determination of changes in bronchodilator use following transition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin requirements in units/day</measure>
    <time_frame>6 months</time_frame>
    <description>Determination of changes in insulin use following transition</description>
  </secondary_outcome>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Cystic Fibrosis (CF)</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Cystic fibrosis with 2 copies of F508del mutation.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of CF

          -  Male or female subjects greater than or equal to 12 years of age

          -  Ability to reproducibly perform spirometry testing

          -  Physician decision to treat with tezacaftor/ivacaftor (Smydeko)

          -  Ability to understand and sign a written informed consent or assent and comply with
             the requirements of the study

          -  Continuous use of orkambi for at least 1 month prior to visit 1

        Exclusion Criteria:

          -  History of hypersensitivity to tezacaftor and/or ivacaftor

          -  Presence of a condition or abnormality that in the opinion of the Investigator would
             compromise the safety of the patient or the quality of the data

          -  Any acute lower respiratory symptoms treated with oral, inhaled or intravenous
             antibiotics (IV) or systemic corticosteroids within the 2 weeks prior to Visit 1

          -  Major or traumatic surgery within 12 weeks prior to Visit 1

          -  For women of child-bearing potential: a positive pregnancy test at Visit 1

          -  Unable or unwilling to fast (including no enteric tube feedings) for at least 6 hours
             prior each visit

          -  Initiation of any new chronic therapy within 4 weeks prior to Visit 1

          -  Use of an investigational agent within 28 days prior to Visit 1

          -  Use of chronic oral corticosteroids within 28 days prior to Visit 1

          -  Treatment for nontuberculous mycobacterial (NTM) infection, consisting of greater than
             or equal to two antibiotics (oral, IV, and/or inhaled) within 28 days prior to Visit 1

          -  History of lung or liver transplantation, or listing for organ transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Terri Herrud, BS</last_name>
    <phone>303-398-1453</phone>
    <email>herrudt@njhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Jewish Heatlh</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri Herrud, BS</last_name>
      <phone>303-398-1453</phone>
      <email>herrudt@njhealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Jewish Health</investigator_affiliation>
    <investigator_full_name>Jennifer Taylor-Cousar</investigator_full_name>
    <investigator_title>MD, Principal Investigator, Co-Director/CF TDN Director, Adult CF Program</investigator_title>
  </responsible_party>
  <keyword>DeltaF508deletion (F508del) mutation in 2 copies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

